Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant super-castration triple androgen blockade before radical prostatectomy for high-risk localized prostate cancer
ACTRN12612000772842Phase 2Completed
- Sponsor
- Dr. Niall Corcoran
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of degarelix, abiraterone, bicalutamide and prednisone in prostate cancer (PCa) (2 arms), sponsored by Dr. Niall Corcoran. Primary endpoints: Safety and tolerability and pT0 response rate. Started Oct 2012; status: completed.
02
Drugs
degarelixabirateronebicalutamideprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12612000772842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000772842.